The Hong Kong listed biotech reported Phase III PASI 100 rates that dwarf the field, then declined to say which 'other agents in the same class' it is comparing against.
Akeso has a new drug and a new story to tell about it. On June 11, 2026, the Hong Kong-listed biotech said China's National Medical Products Administration approved gumokimab, its internally developed anti-IL-17 monoclonal antibody, for adults with moderate-to-severe plaque psoriasis. The approval rests on a single pivotal Phase III trial, AK111-301, and three supportive studies. The data Akeso chose to highlight are striking: 94.6% of patients reached PASI 75 at Week 12, and 47.7% cleared their psoriasis entirely, a PASI 100 response, by the same point. At Week 52, Akeso reported PASI 75 approaching 100% and PASI 100 of 68.9%, with clinically meaningful improvement appearing as early as Week 2.
The problem is the comparison Akeso built around those numbers.
In the same release, Akeso framed gumokimab against what it called "other agents in the same class," claiming a Week 12 PASI 100 of 28.6% and a Week 52 PASI 100 of 39.2% for those unnamed rivals. Those figures are central to the case that gumokimab is best-in-class. The company, however, did not identify a single product by name. No secukinumab. No ixekizumab. No brodalumab, bimekizumab, or netakimab. No citation. No head-to-head trial. The unnamed-comparator framing is doing the work, and the company alone controls the variable.
That matters because the marketed anti-IL-17 field in China is crowded. Novartis's Cosentyx (secukinumab) launched in China years ago. Eli Lilly's Taltz (ixekizumab) and LEO Pharma's brodalumab-based Kyntheum have their own commercial footprints. The category has matured, and pricing pressure is real, which is part of why Akeso's pivot from oncology bispecifics (cadonilimab, ivonescimab) into immunology is strategically notable. A genuine best-in-class claim would be valuable. A claim that cannot be independently checked is something else.
Three concrete items would let a reader evaluate the framing.
First, the NMPA approval record itself. The press release does not include the approval number, the indication wording, or a link to the Chinese-language announcement. Without the official NMPA filing, the comparator claim has no anchor.
Second, the AK111-301 trial registration. ClinicalTrials.gov should show the trial's enrollment size, blinding design, randomization ratio, and the active comparator or placebo arm, if any. A placebo-controlled design is common in pivotal psoriasis studies, and that would explain why gumokimab's numbers look "head and shoulders" above a placebo baseline. Whether AK111-301 was designed against an approved IL-17 inhibitor is the actual question.
Third, a Hong Kong Stock Exchange regulatory disclosure from Akeso (9926.HK). Hong Kong filings require specific commercial claims to be substantiated, and any HKEX announcement dated around June 11, 2026 would be the place to look for a more fulsome data table, including the safety profile. The company characterizes gumokimab's safety and dosing profile as favorable, but the AE/SAE table, immunogenicity, and dose-discontinuation rates were not visible in the public release. Readers, regulators, and prescribing dermatologists will want to see them.
Akeso's broader portfolio context is worth a paragraph. The company built its reputation on PD-1/VEGF bispecifics in oncology, not on autoimmune disease. Gumokimab is being positioned as a cornerstone of a new therapeutic axis, one that diversifies Akeso away from the increasingly competitive Chinese PD-1 market. That is a legitimate corporate story. The "bolstering autoimmune disease portfolio" framing in the headline is the company's own, and it is reasonable to carry it forward with attribution. It is not the same as a verified clinical claim.
The pricing and access question will arrive quickly. China's National Reimbursement Drug List negotiations have reshaped the IL-17 category, and whether gumokimab enters at a premium, a parity price, or with a value-based arrangement will determine how it competes with secukinumab and ixekizumab, both of which have established reimbursement positions. Akeso did not address NRDL posture in the release. That is a watch item, not a fact.
So the cleanest summary is this. Akeso has a regulatory win, and the gumokimab efficacy numbers it disclosed are real. What the press release does not provide is the evidence a careful reader would need to treat the comparative claim as anything more than a marketing construction: a named comparator, a head-to-head trial, an NMPA approval document, a full safety table, and a Hong Kong disclosure that lays out the commercial framing. The next 30 days of disclosures, the AK111-301 record, and the first independent reviews at a dermatology meeting are where this claim either sharpens or softens. For now, gumokimab is approved. Whether it is best-in-class is a question the company has chosen not to answer.